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ABSTRACT
Highly active antiretroviral therapy (HAART) reduces AIDS-related morbidity and mortality, how-
ever it has been associated with metabolic abnormalities. This study estimated the prevalence of lipid 
abnormalities and related factors among patients on HAART. A cross-sectional study was conducted 
on adult patients, in central Brazil. Patients were interviewed, and blood obtained for lipids meas-
urement. Dyslipidemia was defined as total cholesterol (TC) ≥ 240 mg/dL, low-density lipoprotein 
(LDL) ≥ 160 mg/dL, triglycerides (TG) > 200 and/or high-density lipoprotein (HDL) < 40 mg/dL. 
Multiple logistic regression analyses were performed (SPSS 13.0). One hundred and thirteen pa-
tients were recruited. Mean age was 39.3 years; 68.1% were males; 50.4% were on nucleoside reverse 
transcriptase inhibitors (NRTI) in combination with non-nucleoside reverse transcriptase inhibitors 
(NNRTI), while 42.5% were on NRTI in combination with protease inhibitors (PIs). The prevalence 
of dyslipidemia was 66.7%. Low HDL was the most frequent abnormality (53.5%), followed by high 
TG (36.1%). Patients on a PI regimen had a 5.2-fold higher risk (95% CI: 1.8-14.8) of dyslipidemia, 
even after adjusting for sex, age, and duration of HIV infection/AIDS. The study discloses a high 
prevalence rate of dyslipidemia and points out a need for intervention programs to reduce future 
cardiovascular events in patients, on HAART.
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INTRODUCTION
Highly active antiretroviral therapy (HAART) 
reduces the clinical manifestations of HIV in-
fection, delaying the onset of AIDS and sub-
stantially improving the prognosis and quality 
of life of HIV-infected individuals.1,2
Since HAART was first introduced, the 
trend towards a reduced morbidity and mortal-
ity of HIV/AIDS patients has been accompanied 
by the emergence of side effects and toxicities in 
various organs.3 Metabolic abnormalities such 
as dyslipidemias, insulin resistance, hypergly-
cemia and changes in body fat distribution or 
lipodystrophy syndrome are classic examples of 
this situation.4 Side effects reduces adherence to 
treatment, and long term exposure to dyslipi-
demias in this population may increase the risk 
of cardiovascular diseases.5-7
Antiretroviral drugs have been widely avail-
able in Brazil, since 1996 and approximately 
170,000 patients had access to HAART uni-
versally distributed, by the Brazilian National 
Health System (SUS).8 Analyses of the impact of 
HAART in Brazil have shown a pattern similar 
to that described in developed countries, i.e. a 
significant reduction in opportunistic diseases 
with a consequent reduction in AIDS-related 
hospitalizations and mortality.9
Dyslipidemias are estimated to be frequent 
events in patients using HAART; nevertheless, 
up to the present time, few studies have inves-
tigated the prevalence of these abnormalities 
in Brazil.10-12 The present study aimed to esti-
mate the prevalence of dyslipidemias in HIV-
infected patients on antiretroviral therapy, in 
the central part of Brazil, and to evaluate fac-
tors associated with these abnormalities. These 
data may help to predict the impact of long-
term antiretroviral therapy on cardiovascular 
diseases in this group.
MATERIAL AND METHODS
HIV-infected patients over 19 years of age, who 
had been in use of antiretroviral therapy for at 
least 30 days, were eligible to participate in this 
study. All of them were registered in the main re-
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ferral center for HIV/AIDS patients, Hospital for Tropical Dis-
eases Dr. Anuar Auad (HDT/AA), in the city of Goiânia, Goiás.
This is a prevalence study with convenience sampling. 
Sample size was calculated to detect prevalences of dys-
lipidemia ≥ 40% in patients on antiretroviral therapy with 
10% precision, resulting in a required sample of 93 patients. 
Cases were identified between 2005 and 2006.
The protocol was approved by the Internal Review Board 
of the Universidade Federal de Goiás. After obtaining informed 
consent, patients were interviewed, their medical and laboratory 
records abstracted, and blood obtained for laboratory testing. Pa-
tients with a history of opportunistic disease diagnosed less than 
two months prior to the interview were excluded from the study.
A structured interview was administered to all par-
ticipants by the principal investigator to collect social, de-
mographic and clinical data. Patient’s clinical charts were 
also used as data sources from which information on dura-
tion of antiretroviral therapy, T-CD4+ lymphocyte count, 
HIV-1 viral load and previous lipid evaluations was ob-
tained. For the purposes of analyses, viral load measure-
ment was dichotomized into detectable or undetectable, 
and T-CD4+ lymphocyte count was classified as > 350 or 
≤ 350 cells/mL. When more than one laboratory evaluation 
was available, the most recent one was used.
Following the interview, the patients were referred for 
blood lipid evaluation, performed after an overnight fasting 
period. Lipid profile was obtained in individuals who were 
metabolically stable13 by measuring total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL-C) and triglycer-
ides (TG) using an automated enzymatic method. Low-den-
sity lipoprotein cholesterol (LDL-C) was calculated using 
Friedwald’s formula in individuals with triglycerides ≤ 400 
mg/dL. Blood lipids were classified as categorical variables 
and the following situations were defined as dyslipidemia: 
TC ≥ 240 mg/dL, LDL-C ≥ 160 mg/dl, TG > 200 mg/dL and/
or HDL-C < 40 mg/dL.13 To assess cardiovascular risk, Cas-
telli’s Index I was calculated using the ratio: TC/HDL-C; a 
Castelli Index I > 5.1 for men and > 4.4 for women were 
considered indicative of an elevated risk.14
Descriptive and exploratory statistical methods were used: 
measurements of central tendency and dispersion for contin-
uous variables, frequency distributions with their respective 
confidence intervals for categorical variables. Chi-square test 
or Fisher’s exact test were used to evaluate differences in fre-
quency distribution. Student’s t-test was employed to evaluate 
differences between two means, and the Kruskal-Wallis non-
parametric test to evaluate differences in duration of antiret-
roviral therapy. Prevalence rates of dyslipidemia were calcu-
lated with their respective 95% confidence intervals (95% CI).
A case-control analysis was carried out to evaluate the 
association between dyslipidemia and exposure variables. 
Patients with dyslipidemia were considered “cases” and pa-
tients who did not have this condition were considered “con-
trols”. Odds ratios (OR) and their respective 95% confidence 
intervals (95% CI) were calculated. Multiple logistic regres-
sion models were applied with simultaneous adjustment for 
sex, age and length of time since HIV/diagnosis. Interaction 
between exposure variables were also tested to build-up the 
final logistic model. The correlation between the time on 
protease inhibitors and serum HDL levels was evaluated. 
A p-value of less than 0.05 was considered significant. Sta-
tistical analyses were performed using Statistical Package for 
Social Science software (version 13.0).
RESULTS
One hundred and thirteen HIV-infected patients on antiret-
roviral therapy were enrolled. The mean age of participants 
was 39.3 ± 10.4 years, ranging from 20 to 64 years; 68.1% 
were males; 52.2% had less than 9 years of schooling; and ap-
proximately half of them reported very low monthly income 
(≤ one minimum wage). T-CD4+ lymphocyte count > 350 
cells/mL was found in 42.4% of patients, whereas viral load 
was undetectable in 51.9% of participants.
The most frequently prescribed antiretroviral regimen 
consisted of the combination of two nucleoside reverse tran-
scriptase inhibitors (NRTI) with non-nucleoside reverse 
transcriptase inhibitors (NNRTI), used by 50.4% of the sam-
ple, followed by the combination of two NRTI with protease 
inhibitors (PI), used by 42.5% of study participants. Use of 
three distinct classes of antiretroviral drugs (NRTI, NNRTI 
and PI) was recorded for 4.4% of patients. The majority of 
patients (64.6%) were on three drugs; 25.7% on four drugs and 
8.0% on five or more drugs. The most commonly prescribed 
drugs were lamivudine (92.9%), zidovudine (66.4%), and efa-
virenz (49.6%). Fifty-five patients (48.7%) were on at least one PI.
Boosted ritonavir was used with other PI, in 37 patients. 
The most common combination was ritonavir with atazana-
vir, reported by 26 out of 37 patients (62.2%).
Change in body fat distribution, after initiating antiretro-
viral therapy, was perceived by 39.8% of patients, with abdom-
inal fat accumulation being the most frequently mentioned 
(91.1%). Less than half the patients (45.1%) reported having 
previous lipid assessment, and 47.0% of these patients report-
ed increased cholesterol and/or triglyceride levels. Among 
those who reported abnormal blood lipid levels, 20.8% were 
on lipid-lowering drugs.
Out of 113 patients interviewed, 97 had were on antiretrovi-
ral therapy for at least 30 days and were evaluated with respect 
to their lipid profile. Length of time on PI was significantly 
shorter than the time on either NRTI or NNRTI (p < 0.043).
Table 1 shows the results of the Castelli Index I according 
to sex and the lipid profile of 97 patients evaluated in accord-
ance with the Brazilian Cardiology Society (SBC) classifica-
tion. Among men 36.9% had a Castelli Index I > 5.1, whereas 
40% of the women had a Castelli Index I > 4.4, indicating a 
higher risk of cardiovascular disease in this population.
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The majority of patients (66.7%) had at least one 
laboratory abnormality compatible with a diagnosis of 
dyslipidemia. The most frequent abnormality was low 
HDL-C, levels below 40 mg/dL being found in 53.7% 
of participants. Additionally, 36.1% of the participants 
had triglyceride levels > 200 mg/dL. HDL-C < 40 mg/dL 
and triglycerides > 200 mg/dL was the most common 
mixed dyslipidemia, being diagnosed in 27.4% of par-
ticipants.
Age, duration of HIV/AIDS, sex, viral load measurement 
and immunological status evaluated by T-CD4+ cell were 
not significantly different between dyslipidemic and non-
dyslipidemic patients.
In univariate analysis patients on PI had 3.4-fold greater 
risk (95% CI: 1.4-8.4) of dyslipidemia compared to patients 
on regimens that did not include this class of drugs. On 
the other hand, patients on NNRTI-containing regimens 
had lower risk of dyslipidemia (OR = 0.3; 95% CI: 0.1-0.6). 
Nevertheless, a significant interaction (p < 0.003) was found 
between these exposure variables (being on a PI-containing 
regimen or on an NNRTI-containing regimen) and the pres-
ence of dyslipidemia.
PI were independently associated with dyslipidemia 
even after simultaneous adjustment for potential confound-
ing factors such as sex, age and duration of HIV infection 
(ORadjusted = 5.2; 95% CI: 1.8-14.8) as shown in Table 2. There 
was no correlation between duration of PI use (in months) 
and serum HDL-C level (r = - 0.2; p = 0.12).
DISCUSSION
The present study discloses a high prevalence of dyslipi-
demia in patients on antiretroviral therapy in a large city in 
central Brazil. These findings suggest a potential risk for the 
development of cardiovascular diseases in a significant pro-
portion of HIV/AIDS patients in coming years. Therefore, 
the benefits obtained with the use of HAART over the past 
years may be reduced if measures to minimize the negative 
impact of cardiovascular disease in this population are not 
implemented.
Table 1. Lipid profile of patients using antiretroviral 
therapy
Variable (mg/dL) Frequency Percentage 95% CI
Total cholesterol   
 Optimal (< 200) 70 72.2 62.1 - 80.8
 Borderline high 17 17.5 10.6 - 26.6 
 (200 - 239)   
	 High	(≥	240)	 10	 10.3	 5.0	-	18.1
HDL cholesterola
 Low (< 40) 51 53.7 43.1 - 64.0
 Optimal (> 60) 44 46.3 36.0 - 56.8
LDL cholesterolb
 Optimal (< 100) 45 50.6 39.7 - 61.3
 Desirable 26 29.2 20.0 - 40.0 
 (100-129)
 Borderline high 13 14.6 8.0 - 23.7 
 (130-159)
 High (160-189) 3 3.4 0.7 - 9.5
	 Very	high	(≥	190)	 2	 2.2	 0.3	-	7.9
Triglycerides
 Optimal (< 150) 51 52.6 42.2 - 62.8
 Borderline high 11 11.3 5.8 - 19.4 
 (150-200)
 High 32 33.0 23.8 - 43.3 
 (201-499)
	 Very	high	(≥	500)	 3	 3.1	 0.6	-	8.8
Castelli Index Ia,c,d
 Men > 5.1 24 36.9 25.5 - 49.8
 Women > 4.4 12 40.0 23.2 - 59.3
HDL, high density lipoprotein; LDL, low density lipoprotein. 
aData missing for 2 patients.
bData missing for 8 patients.
cCastelli Index I, total cholesterol/HDL cholesterol.
d65 male and 30 female participants.
Table 2. Multiple logistic regression analysis of factors associated with dyslipidemia
Variable % dyslipidemia OR ( 95%CI) ORadjusted (95% CI) p
Use of PI 79.6 3.4 (1.4-8.4) 5.2 (1.8-14.8) 0.002*
Male 71.2 1.9 (0.8-4.6) 2.7 (1.0-7.6) 0.053
Age (years) - - 1.0 (1.0-1.1) 0.013*
Time of HIV (months) - - 1.0 (1.0-1.0) 0.360
PI, protease inhibitors; HIV, human immunodeficiency virus. 
Age and time of diagnosis of HIV/AIDS were included in the model as continuous variables.
OR adjusted for sex, age and time of diagnosis of HIV infection/AIDS.
* Statistically significant association.
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The majority of HIV-infected patients on HAART, in our 
setting, were found to have abnormal lipid profile with po-
tential risk for cardiovascular disease in a near future.7
Patients using lipid-lowering therapy were not excluded 
from the present analysis, and, unexpectedly, all of them had 
some lipid abnormality compatible with the diagnosis of 
dyslipidemia, suggesting the need for better clinical control, 
in accordance with the recommendations guidelines.13,15
There are wide variations in the prevalence rate of dyslip-
idemia among HIV-infected patients on antiretroviral ther-
apy. Comparison of results from different prevalence studies 
should be made with caution, taking into consideration dif-
ferences in methodology, populations studied, antiretroviral 
regimens used by the patients, and the cut-off points estab-
lished to define lipid abnormalities. For the purpose of clini-
cal management, the current trend is to attempt to lower 
blood lipid levels; hence, the cut-off point for the definition 
of lipid abnormalities is lower.13 However, in the present 
study, it was decided to apply more conservative criteria 
with higher cut-off limits to define dyslipidemia, thereby 
guaranteeing greater specificity of results. The percentage 
of lipid abnormalities encountered in this study would have 
been even higher if lower cut-off points had been used.
In our sample, low HDL was the most frequent ab-
normality (53.7% of patients had levels < 40 mg/dL), fol-
lowed by elevated triglyceride levels (36.1% of patients 
had levels > 200 mg/dL). Approximately 40% of patients 
had an elevated Castelli Index I, indicating an increased risk 
for atherosclerotic cardiovascular disease in this population. 
This index is considered a simple approach for lipid risk as-
sessment, the high total cholesterol is a marker for athero-
genic lipoproteins and low HDL cholesterol correlates with 
risk factors of metabolic syndrome.14,16
Few studies on the prevalence of dyslipidemia carried 
out in Brazil have been published.10-12 In the northeast re-
gion, a cross-sectional study12 conducted among a sample of 
372 patients with and without antiretroviral therapy found 
high TC, low HDL and high TG levels in 20.1%, 57.1% and 
26.5% of subjects, respectively. A study conducted in the 
southeast11 involving 238 patients, predominantly using PI, 
found low HDL in 65% of participants and hypertriglyceri-
demia in 46% of them, using different cut-off points from 
those used in our study. 
Different antiretroviral drugs may be associated with 
abnormalities in lipid profile. Various studies have shown 
an association between the use of PI and dyslipidemia.5,7,12 
The prevalence and degree of lipid abnormalities, however, 
vary between the different drugs, within a single class and 
possibly with duration of treatment.17 The present study was 
not designed to evaluate differences between drugs within 
the same class. The use of PI was associated with the pres-
ence of dyslipidemia even after simultaneous adjustment for 
possible confounding factors such as sex, age and time since 
diagnosis of HIV/AIDS. The duration of PI use was not in-
cluded in the logistic regression model. Nevertheless, there 
was no evidence of any correlation between duration of PI 
use and serum HDL-C levels (p = 0.12). Contrary to our 
findings, another study conducted in Brazil11 reported a cor-
relation between duration of PI use and HDL-C levels.
The association between NNRTI use and dyslipi-
demias is controversial. A growing number of reports 
suggest that use of this class of drugs may lead to an 
increase in lipids.17,18 In agreement with our results, an-
other study conducted in London19 found no increase 
in total cholesterol or in triglycerides in patients on 
NNRTI. Other investigators have reported an increase 
in HDL-C in patients on this class of drugs, which may 
have a protective effect against the development of coro-
nary disease.20
One of the limitations of the present study is not hav-
ing included the cumulative history of the prior use of 
antiretrovirals. It is possible that patients on PI, mainly 
those on ritonavir-boosted regimens, may have had the 
disease for a longer time and may have been exposed 
to various drugs previously, which may have interfered 
in their current lipid profile. To minimize this effect, 
an estimation of the time of HIV infection/AIDS was 
included in the logistic regression model as surrogate 
marker for the time of use of antiretroviral drugs.
Some other methodological issues with respect to 
the site at which cases were recruited and the sampling 
process should also be mentioned. Patients registered at 
the principal referral service for HIV/AIDS in the state 
of Goiás were recruited to this study. This referral center 
is responsible for the notification of almost all cases of 
AIDS in the state. 
Despite 48.1% of these patients had a detectable viral 
load we cannot conclude that they were inappropriately 
treated. Viral load assessment is used to monitor ther-
apy and around half these patients underwent a change 
in their antiretroviral regimen following evaluation of 
plasma viremia.
Assuming that the sample of patients studied is rep-
resentative, our results indicate a high prevalence of 
dyslipidemia and risk for the development of cardiovas-
cular disease in a significant proportion of patients with 
HIV/AIDS in the years to come in central part of Brazil. 
Furthermore, as most of patients unaware of their lipid 
abnormalities, the findings of this study underscore the 
need to adopt strategies to routinely evaluate and modi-
fy the risk of cardiovascular diseases in this population.
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